Alzheimer's Disease Ion Channel Modulator Companies

Overview

This category page covers biotechnology and pharmaceutical companies developing ion channel modulators for Alzheimer's disease (AD). Ion channels represent a promising therapeutic target for neurodegeneration, with companies targeting:

Overview

This category page covers biotechnology and pharmaceutical companies developing ion channel modulators for Alzheimer's disease (AD). Ion channels represent a promising therapeutic target for neurodegeneration, with companies targeting:

• Potassium channels (Kv7/KCNQ family) — neuronal hyperexcitability and neuroprotection
• Calcium channels (L-type, T-type, P/Q-type) — calcium dysregulation and excitotoxicity
• Sodium channels — neuronal firing patterns and excitotoxicity

Scientific Rationale

Potassium Channel Modulators

The Kv7 (KCNQ) family of potassium channels regulates neuronal excitability by stabilizing the resting membrane potential. In AD, Kv7 channels are implicated in:

• Amyloid-beta toxicity: Kv7 activation protects neurons from Aβ-induced cytotoxicity
• Synaptic function: Kv7 modulators improve synaptic plasticity and memory
• Hyperexcitability: Restoring normal firing patterns reduces seizure-like activity in AD models
• Neuroprotection: Kv7 activation reduces oxidative stress and mitochondrial dysfunction[@milligan2020]

Calcium Channel Modulators

Calcium dysregulation is a hallmark of AD, with excessive calcium influx leading to:

• Excitotoxicity: Overactivation of NMDA receptors and downstream cell death pathways
• Tau phosphorylation: Calcium-dependent kinases promote NFT formation
• Neuroinflammation: Calcium-activated microglia release pro-inflammatory cytokines
• Mitochondrial dysfunction: Calcium overload impairs energy production[@calciumpd2023]

Sodium Channel Modulators

Voltage-gated sodium channels contribute to AD pathophysiology through:

• Neuronal hyperexcitability: Increased firing patterns and seizure activity
• Dendritic spine loss: Sodium dysregulation affects synaptic structure
• Glutamate toxicity: Dysregulated sodium channels exacerbate excitotoxicity
• Network oscillations: Altered sodium channel function disrupts brain rhythms[@sodiumpd2021]

Key Companies

Potassium Channel Modulators

Biohaven Pharmaceutical Holding Company Ltd.

• Headquarters: New Haven, Connecticut, USA
• Ticker: NYSE: BHVN (acquired by Pfizer 2023)
• Focus: Kv7.2/7.3 (KCNQ2/3) potassium channel activators
• Lead Programs:
• Troriluzole (BHVN-4151): Kv7 activator in Phase 2 for AD
• BHVN-7010: Next-generation Kv7 activator, Phase 1
• Pipeline:

• Technology: Acquired Kv7 platform from Bristol-Myers Squibb (2018)
• Relevance: Oral bioavailability, established safety, BBB penetration
• See: [Biohaven](/companies/biohaven)

Cerevel Therapeutics

• Headquarters: Boston, Massachusetts, USA
• Ticker: NASDAQ: CREV
• Focus: Kv7.2/7.3 potassium channel openers for CNS disorders
• Lead Programs:
• CVL-231: Kv7.2/7.3 opener, Phase 2 for AD
• Pipeline:

• Technology: Formerly part of Pfizer, spun out 2020
• See: [Cerevel Therapeutics](/companies/cerevel-therapeutics)

Quralis

• Headquarters: San Diego, California, USA
• Focus: Kv7.2/7.3 modulators for neurodegenerative diseases
• Lead Programs: Kv7 targeting compounds in preclinical development
• Technology: Novel chemistry platform for CNS ion channel modulators
• See: [Quralis](/companies/quralis)

Lysoway Therapeutics

• Headquarters: Cambridge, Massachusetts, USA
• Focus: Lysosomal potassium channel (TMEM175) agonists
• Lead Programs: TMEM175 modulators for PD and AD
• Relevance: TMEM175 regulates lysosomal pH and autophagy; dysfunction linked to neurodegeneration
• Mechanism: Small molecule agonists of TMEM175 lysosomal potassium channel
• See: [Lysoway Therapeutics](/companies/lysoway-therapeutics)

Calcium Channel Modulators

Daiichi Sankyo Co., Ltd.

• Headquarters: Tokyo, Japan
• Ticker: TYO: 4568
• Focus: α2δ subunit calcium channel modulators
• Marketed Products:
• Tarlige (mirogabalin): α2δ calcium channel blocker approved for neuropathic pain
• Pipeline:

• Technology: Established calcium channel modulation platform
• Relevance: Mirogabalin's mechanism is applicable to calcium dysregulation in AD
• See: [Daiichi Sankyo](/companies/daiichi-sankyo)

Accerise Inc.

• Headquarters: Tokyo, Japan
• Founded: 2016
• Focus: Structure-based drug design for CNS disorders, calcium channel modulators
• Lead Programs:
• ACC-004: T-type and L-type calcium channel modulator for PD/AD
• Pipeline:

• Technology: Proprietary structure-based drug design platform with cryo-EM and computational modeling
• Scientific Rationale: T-type channels (Cav3.1, Cav3.2) contribute to neuronal hyperexcitability; L-type channels (Cav1.3) show altered function in aging neurons
• See: [Accerise Inc.](/companies/accerrise)

Sodium Channel Modulators

Teva Pharmaceutical Industries Ltd.

• Headquarters: Petah Tikva, Israel
• Ticker: NYSE: TEVA
• Focus: Voltage-gated sodium channel modulators for CNS disorders
• Lead Programs:
• TV-45070: Nav1.7/1.8 sodium channel blocker for PD and pain
• Pipeline:

• Technology: Sodium channel blockade reduces neuronal firing patterns associated with movement disorders
• Relevance: May address motor symptoms and dyskinesias beyond dopaminergic approaches
• See: [Teva Pharmaceuticals](/companies/teva-pharmaceuticals)

Vertex Pharmaceuticals

• Headquarters: Boston, Massachusetts, USA
• Ticker: VRTX
• Focus: Non-addictive pain treatments via sodium channel inhibitors
• Technology: NaV1.8 inhibitors provide analgesia without CNS effects
• Pipeline: Sodium channel programs in development for pain, potential AD applications
• See: [Vertex](/companies/vertex)

Grünenthal GmbH

• Headquarters: Aachen, Germany
• Focus: Sodium channel blockers for pain and CNS disorders
• Lead Programs: NaV1.7 and NaV1.8 selective inhibitors
• Partnerships: Novartis (early-stage pain programs), AstraZeneca (CNS disorders including AD)
• See: [Grünenthal](/companies/grunenthal)

Shionogi & Co., Ltd.

• Headquarters: Osaka, Japan
• Ticker: TYO: 4507
• Focus: Selective sodium channel blockade
• Lead Programs: S-010887 targeting NaV1.7 for pain
• Technology: Novel chemical scaffolds for selective sodium channel inhibition
• See: [Shionogi](/companies/shionogi)

Axxonis Pharma AG

• Headquarters: Heidelberg, Germany
• Focus: Sodium channel modulation and neuroprotection
• Technology: Novel sodium channel modulators with neuroprotective properties
• See: [Axxonis](/companies/axxonis)

Competitive Landscape

| Company | Primary Mechanism | AD Focus | Key Asset | Stage |
|---------|-------------------|----------|-----------|-------|
| Biohaven | Kv7 potassium activator | Yes | Troriluzole | Phase 2 |
| Cerevel | Kv7 potassium opener | Yes | CVL-231 | Phase 2 |
| Daiichi Sankyo | α2δ calcium channel | Yes | Mirogabalin (repurposing) | Approved |
| Accerise | T-type/L-type calcium | Yes | ACC-004 | Discovery |
| Lysoway | Lysosomal K+ channel | Emerging | TMEM175 agonists | Preclinical |
| Teva | NaV1.7/1.8 | Emerging | TV-45070 | Phase 2 |
| Vertex | NaV1.8 inhibitor | Emerging | Pipeline | Discovery |
| Grünenthal | NaV1.7/1.8 | Emerging | Pipeline | Discovery |

Therapeutic Potential in AD

Disease-Modifying Mechanisms

Clinical Development Considerations

• Biomarker strategies: EEG, calcium imaging, and synaptic markers for patient selection
• Combination approaches: Ion channel modulators combined with amyloid/tau-targeting therapies
• Genetic stratification: Targeting patients with ion channel genetic variants
• Delivery methods: Oral, intranasal, and transdermal formulations for optimal brain penetration

Cross-References

• [Alzheimer's Disease - Therapeutic Approaches](/diseases/alzheimers-disease)
• [Potassium Channels in Neurodegeneration](/mechanisms/potassium-channel-dysfunction)
• [Calcium Channel Dysfunction in Alzheimer's Disease](/mechanisms/calcium-dysregulation-pathway)
• [Sodium Channel Biology in Neurodegeneration](/cell-types/sodium-channel-neurons)
• [Kv7 Potassium Channels](/proteins/kcnq2-protein)
• [T-type Calcium Channels](/proteins/cacna1g-protein)
• [L-type Calcium Channels](/proteins/l-type-ca)

External Links

• [PubMed - Ion Channel Modulators in AD](https://pubmed.ncbi.nlm.nih.gov/?term=Alzheimer+ion+channel+modulators)
• [ClinicalTrials.gov - Ion Channel AD](https://clinicaltrials.gov/search?cond=Alzheimer+disease&intr=ion+channel)
• [Nature Reviews - Calcium in Neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/37855612/)

References